Mounjaro: the current scenario in Brazil and worldwide, scientific evidence, and impacts on aesthetics -

Introduction
Mounjaro® (tirzepatide) is a medication originally developed to treat type 2 diabetes, but it quickly gained popularity due to its significant weight loss results. Recently, it has become a topic of discussion not only among endocrinologists but also within the aesthetics field, raising debates about the scientific evidence, ethical issues, and regulations surrounding its use. This article explores the current status of Mounjaro in Brazil and worldwide, based on scientific findings and market trends.

What is Mounjaro and how does it work?
Tirzepatide mimics the action of two hormones simultaneously: GIP and GLP-1. This results in:

Reduced appetite
Increased feeling of satiety after meals
Improved blood glucose control
Significant weight loss

Studies indicate that tirzepatide may lead to greater weight loss than other similar medications, such as semaglutide, especially in individuals with obesity associated with comorbidities.

Mounjaro in Brazil
In Brazil, Mounjaro gained attention soon after being approved by Anvisa. Initially indicated only for type 2 diabetes, it quickly began to be discussed for weight loss and aesthetic purposes.

Current situation in Brazil:

High public interest in its effectiveness and safety
High cost, limiting access
Increasing medical prescriptions
Ongoing debates about its aesthetic use outside approved indications

There is growing interest among healthcare professionals, aesthetic students, and individuals seeking weight loss.

Worldwide scenario
In countries such as the United States, the United Kingdom, and several European nations, Mounjaro has already become widely used. Physicians prescribe it for both diabetes and obesity.

Global trends include:

Rapid growth in usage
Approval and use for obesity treatment
Ongoing long-term safety studies
Frequent comparisons with Ozempic® and Wegovy®

International experts suggest that tirzepatide may become one of the most widely used obesity treatments in the coming years due to its high effectiveness in selected patients.

Impacts on aesthetics
In the aesthetics field, Mounjaro is seen as a tool to reduce body fat, improve body contouring, and lower BMI. However, specialists warn about possible adverse effects, such as:

Loss of muscle mass
Skin flaccidity
Metabolic changes

Therefore, aesthetic use of Mounjaro must be carefully evaluated, always under professional supervision and with a focus on overall health.

Ethical and scientific considerations
Despite promising results, the indiscriminate use of Mounjaro raises ethical concerns. It does not replace a healthy lifestyle, and its use for purely aesthetic purposes must be guided by scientific evidence and safety criteria.

Studies emphasize that obesity treatment should be multidisciplinary, involving lifestyle changes, nutritional guidance, and continuous medical monitoring.

Conclusion
Mounjaro represents an important advancement in the treatment of type 2 diabetes and obesity and is significantly influencing the aesthetics field. In Brazil and worldwide, interest continues to grow due to visible results and increasing public awareness. However, its use must be cautious, evidence-based, and guided by safety and ethical principles.

Brazil

ANVISA. Anvisa approves the use of the medication Mounjaro (tirzepatide) for weight loss. Brasília, 2025. Available at: https://www.gov.br/anvisa. Accessed on: Jan. 19, 2026.

AGÊNCIA BRASIL. Anvisa approves Mounjaro for the treatment of obesity and overweight with comorbidities. Brasília, 2025. Available at: https://agenciabrasil.ebc.com.br. Accessed on: Jan. 19, 2026.

CNN BRASIL. Brazil is the second country that most searches for Mounjaro and Ozempic worldwide. São Paulo, 2024. Available at: https://www.cnnbrasil.com.br. Accessed on: Jan. 19, 2026.

FEDERAL COUNCIL OF PHARMACY (CFF). Launch of Mounjaro in Brazil: indications, price, and regulation. Brasília, 2025. Available at: https://site.cff.org.br. Accessed on: Jan. 19, 2026.

International

ELI LILLY AND COMPANY. Mounjaro™ (tirzepatide): clinical efficacy and safety results. Indianapolis, 2024. Available at: https://investor.lilly.com. Accessed on: Jan. 19, 2026.

JASTREBOFF, A. M. et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, v. 387, n. 3, p. 205–216, 2022. DOI: 10.1056/NEJMoa2206038.

RUBINO, D. et al. Effect of tirzepatide on body weight in adults with obesity. The Lancet, v. 400, n. 10355, p. 711–722, 2022. DOI: 10.1016/S0140-6736(22)01426-6.

REUTERS. Eli Lilly plans global expansion of Mounjaro, including Brazil and emerging markets. London, 2025. Available at: https://www.reuters.com. Accessed on: Jan. 19, 2026.

U.S. FOOD AND DRUG ADMINISTRATION (FDA). FDA approves tirzepatide for the treatment of type 2 diabetes. Silver Spring, 2022. Available at: https://www.fda.gov. Accessed on: Jan. 19, 2026.